Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. - Wu, Y.; Amonkar, M. M.; Sherrill, B. H.; O’Shaughnessy, J.; Ellis, C.; Baselga, J.; Blackwell, K. L.; Burstein, H. J. (Annals of Oncology, 2011)